Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | IAPP | P10997 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28159137 | 0.88 | IAPP (0.46) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL1337385 | 0.86 | FFAR4 (0.47) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL29680321 | 0.79 | FFAR4 (0.50) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL4639208 | 0.79 | FFAR4 (0.50) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL956388 | 0.79 | CYP4F2 (0.48) | ALDH1A1KMT2ARIPK1IAPPSMN1; SMN2 | |
| SCHEMBL3456260 | 0.78 | RIPK1 (0.41) | RIPK1IAPP | |
| SCHEMBL30428005 | 0.78 | FFAR4 (0.49) | FFAR4ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16070965 | 0.77 | IAPP (0.56) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL4322411 | 0.77 | CES2 (0.42) | FFAR4ALDH1A1MEN1KMT2ACES2 | |
| SCHEMBL28815478 | 0.77 | ALDH1A1 (0.46) | MMP12CXCL8FFAR4ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043335-A1 | Such as N-methyl-2-(2-(2-(2,3-difluorophenyl)ethyl)-7-(3-dimethylaminoprop-1-yl)-4-oxo-4H-quinolin-1-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)acetamide bitartrate; plateley activating factor acetylhydrolase inhibitors; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2005-02-24 | — | — | US | disclosed |
| EP-1442020-A1 | HETEROCYCLIC DERIVATIVES OF GLYCINAMIDE AND THEIR MEDICAL USE | SmithKline Beecham plc (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003042179-A1 | HETEROCYCLIC DERIVATIVES OF GLYCINAMIDE AND THEIR MEDICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043335-A1 | Such as N-methyl-2-(2-(2-(2,3-difluorophenyl)ethyl)-7-(3-dimethylaminoprop-1-yl)-4-oxo-4H-quinolin-1-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)acetamide bitartrate; plateley activating factor acetylhydrolase inhibitors; for treatment of atherosclerosis | PLA2G7, PAFAH1B2, PLAAT2 | MMP12 118/4885CXCL8 2601/4885FFAR4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.